TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A Chalmers University of Technology study found overlapping blood-protein patterns in triglyceride-rich lipoproteins and Lp(a), particles that may contribute to heart disease risk beyond LDL cholesterol. The findings suggest possible biological pathways for future prevention research, but the study did not test a treatment or establish a clinical protein test.
Researchers at Chalmers University of Technology have identified blood-protein patterns associated with the ways two types of fat-carrying particles, TRL and Lp(a), may contribute to heart disease risk even when LDL cholesterol is lowered. The study offers clues about biological processes for future research, but it did not test a new treatment or establish a protein test for clinical use.
The team combined measurements of almost 3,000 blood proteins with genetic data and long-term health records. It compared patterns linked to three types of apolipoprotein B-containing lipoproteins: LDL, triglyceride-rich lipoprotein (TRL) and lipoprotein(a), or Lp(a). Each can carry cholesterol that may accumulate in artery walls.
The researchers found that TRL and Lp(a) shared many protein patterns, including proteins associated with attracting immune cells. The team said those processes could contribute to inflammation and changes in blood-vessel walls. By contrast, the protein pattern associated with LDL was mainly linked to cholesterol buildup in artery walls.
The findings, reported in the European Heart Journal in a study titled “Apolipoprotein B-containing lipoproteins: distinct roles in atherosclerosis revealed by plasma proteomic profiling,” are observational clues about potential mechanisms. They do not show that the proteins cause disease, or that changing them would prevent heart attacks.
How Risk Beyond LDL May Develop
Lowering LDL cholesterol substantially reduces heart attack risk, but it does not remove all risk for every person. The study addresses one possible reason: other cholesterol-carrying particles may be linked to biological effects that are not captured by LDL levels alone.
If further work confirms these pathways, they could help researchers identify people who might benefit from more tailored prevention or develop ways to target risk beyond LDL. For now, that is a research prospect, not a change to current care. The study’s lead, Clemens Wittenbecher, said lowering LDL remains a cornerstone of prevention.
Popular right now
Dyson V8 Cyclone Cordless Vacuum
Bose QuietComfort Ultra Wireless Noise-Cancelling Headphones with Spatial Audio, Black
TCL QM64L 85-Inch QD-Mini LED 4K Smart Fire TV
As an affiliate, we earn on qualifying purchases.
What the Researchers Compared
Coronary heart disease develops when fatty material accumulates in vessels supplying the heart. LDL, often called “bad” cholesterol, is a well-established risk factor, and treatments that lower it reduce heart attack risk. Yet some people develop coronary disease even after treatment brings LDL cholesterol to a recommended level.
A previous study by the same research group found that counting harmful lipoprotein particles predicted future heart disease risk more effectively than some other measures, according to the report. It also indicated that TRL and Lp(a) may be more harmful per particle than LDL. The current study examined protein patterns that could help explain how these particles affect the body; it does not replace the established role of LDL reduction.
The researchers used proteomics, which measures many proteins in a sample, alongside genetic information and health records. The report cites the World Health Organization’s estimate that about 17.9 million people die from cardiovascular diseases each year; heart attacks and strokes account for more than four out of five such deaths.
““For this study, we wanted to understand what happens beyond the accumulation of cholesterol in artery walls, whether different fat-carrying particles can damage the blood vessels differently and why the remaining risk of heart disease still occurs.””
— Jakub Morze, study lead author and postdoctoral fellow at Chalmers University of Technology
What the Protein Patterns Cannot Show
The findings do not establish that the identified proteins directly cause artery damage or future heart disease. Protein patterns can be associated with biological processes without proving that one causes another, and the report does not show that changing these patterns reduces risk.
It is also unclear whether measuring the proteins would improve risk assessment in routine care, which patients might benefit from such measurements, or whether any of the suggested processes can be safely targeted. The researchers did not test a new therapy, validate a clinical test, or report evidence that people should alter their treatment based on these results.
Testing Whether Findings Improve Prevention
The researchers say the next step is to determine whether measuring or targeting the identified biological processes can improve prevention alongside existing treatments. That will require follow-up research to test whether the protein patterns predict outcomes reliably and whether interventions based on them make a difference to patients.
Until such evidence is available, the study’s findings remain a basis for investigation rather than a clinical recommendation. The report says LDL lowering remains central to prevention; decisions about cardiovascular risk and treatment should be made with a qualified health professional.
Key Questions
What did the Chalmers study find?
It found overlapping blood-protein patterns associated with TRL and Lp(a), two particles that may contribute to heart disease risk beyond LDL. The patterns included proteins linked to immune-cell activity and possible inflammatory and blood-vessel processes.
Does the study show that TRL and Lp(a) cause heart disease?
No. The study identified associations and possible biological clues; it did not prove that the proteins or particles cause disease.
Does this research change how LDL cholesterol is treated?
No treatment change was tested or recommended in the report. Study leader Clemens Wittenbecher said lowering LDL remains a cornerstone of prevention.
Is there a new blood test based on these findings?
No clinical protein test was established by the study. Whether measuring these patterns would improve prevention remains a question for future research.
What happens next?
Researchers plan to investigate whether measuring or targeting the identified processes can improve prevention alongside existing treatments. The study does not provide a timeline for that work.
Source: rss
